New onset diabetes after transplantation (NODAT): Analysis of pre-transplant risk factors in renal allograft recipients

Prakash, Jai; Rathore, Surendra Singh; Singh, Tara; Choudhury, Tauhidul Alam; Prabhakar, .; Usha, .

doi:10.1016/j.ijt.2012.07.003

Cited by 17 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study conducted by Valderhaug TG et al, posttransplant diabetes mellitus (PTDM) was reported in 14% patients [16]. In Indian studies, the incidences of NODAT were [17][18][19]. So there has been wide variation among incidence and in our study, the incidence of NODAT is 24%.…”

Section: Discussionsupporting

confidence: 48%

An observational prospective study to evaluate the outcomes of new onset diabetes after renal transplantation (NODAT) in a tertiary care centre in eastern India

Kumar

Sanyal

Das

et al. 2020

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 48%

An observational prospective study to evaluate the outcomes of new onset diabetes after renal transplantation (NODAT) in a tertiary care centre in eastern India

Kumar

Sanyal

Das

et al. 2020

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…[ 13 ] in his study found PTDM in 14% patients. From Indian studies the incidences of NODAT were 19.12% by Prakash et al .,[ 14 ] while Sharma et al . [ 15 ] and Bora et al .…”

Section: Discussionmentioning

confidence: 99%

“…In Indian study by Prakash et al . [ 14 ] mean age of NODAT was 40.4 and in non-NODAT it was 31.13. The mean age of our subjects was 45.2 ± 10.93 years and 36.04 ± 10.56 years in NODAT and non-NODAT groups, respectively.…”

Section: Discussionmentioning

confidence: 99%

An observational prospective study to evaluate the preoperative risk factors of new-onset diabetes mellitus after renal transplantation in a tertiary care centre in Eastern India

Kumar

Sanyal

Das

et al. 2018

Indian J Endocr Metab

View full text Add to dashboard Cite

Objectives:This study aimed to determine the pre-transplant risk factors as independent predictors on the new-onset of diabetes mellitus after renal transplants (NODATs).Materials and Methods:A single-centred prospective real-world observational study of 100 subjects who underwent renal transplantation over a period of 2 years. All known patients with diabetes were excluded from the study. NODAT was defined according to the American Diabetes Association definition. In addition to pre-transplant workup 2 days prior to transplant, post-transplant follow-up done on weekly basis for 1st month, every 15th day from 1st month to 3rd month, monthly from 3rd month to 12th month. Each transplant patient followed up for 1 year post-transplant or for 6 months post-development of NODAT, whichever was later. All the pre-transplant variables namely body mass index (BMI), family history of diabetes mellitus (DM), HbA1c, fasting insulin level, fasting c-peptide level, serology for hepatitis B, C, serum magnesium level and pre-operative insulin ressistance were further compared between NODAT and non-NODAT groups at the end of the study to assess their strength of associations.Results:Among the 100 subjects included in the study, 24 developed NODAT. Risk factors namely age, family history of DM, BMI, hepatitis B and C infection, total cholesterol, triglyceride level, pre-operative HbA1c, pre-operative insulin resistance and pre-diabetes were significantly higher, whereas beta-cell function, ABO compatibility and magnesium levels being significantly lower in NODAT cohort.Conclusion:The incidence of NODAT is quite high (24%). Risk of development of NODAT was related to traditional as well as novel risk factors. Key aspects lies in identifying patients at risk of developing NODAT, using traditional risk factors for early diagnosis and introducing interventions on modifiable risk factors for prevention and timely intervention.

show abstract

“…The identification of the same abnormality in the general ADPKD population would eventually require a much larger sample size to be revealed. The conclusions from the different authors are extremely heterogeneous, some of them reporting a positive association between transplantation and NODAT [21][22][23][24][25][26][27][28][29] while others not confirming the association [30][31][32][33][34][35].…”

Section: Potential Defects In Glucose Handling In Adpkd Patientsmentioning

confidence: 99%

Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans

Magistroni

Boletta²

2017

J Nephrol

View full text Add to dashboard Cite

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disease characterized by bilateral renal cyst formation. ADPKD is one of the most common rare disorders, accounting for ~10% of all patients with end-stage renal disease (ESRD). ADPKD is a chronic disorder in which the gradual expansion of cysts that form in a minority of nephrons eventually causes loss of renal function due to the compression and degeneration of the surrounding normal parenchyma. Numerous deranged pathways have been identified in the cyst-lining epithelia, prompting the design of potential therapies. Several of these potential treatments have proved effective in slowing down disease progression in pre-clinical animal studies, while only one has subsequently been proven to effectively slow down disease progression in patients, and it has recently been approved for therapy in Europe, Canada and Japan. Among the affected cellular functions and pathways, recent investigations have described metabolic derangement in ADPKD as a major trait offering additional opportunities for targeted therapies. In particular, increased aerobic glycolysis (the Warburg effect) has been described as a prominent feature of ADPKD kidneys and its inhibition using the glucose analogue 2-deoxy-D-glucose (2DG) proved effective in slowing down disease progression in preclinical models of the disease. At the same time, previous clinical experiences have been reported with 2DG, showing that this compound is well tolerated in humans with minimal and reversible side effects. In this work, we review the literature and speculate that 2DG could be a good candidate for a clinical trial in humans affected by ADPKD.

show abstract

New onset diabetes after transplantation (NODAT): Analysis of pre-transplant risk factors in renal allograft recipients

Cited by 17 publications

References 31 publications

An observational prospective study to evaluate the outcomes of new onset diabetes after renal transplantation (NODAT) in a tertiary care centre in eastern India

An observational prospective study to evaluate the outcomes of new onset diabetes after renal transplantation (NODAT) in a tertiary care centre in eastern India

An observational prospective study to evaluate the preoperative risk factors of new-onset diabetes mellitus after renal transplantation in a tertiary care centre in Eastern India

Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans

Contact Info

Product

Resources

About